Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Orchid Chemicals & Pharmaceuticals — Investor Presentation (April 2010)
29 slides from Orchid Pharma's investor presentation, April 2010
Slide 1: Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation
Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation April 2010 www.orchidpharma.com 1
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements / projections, which are based on current expectations and forecasts about future events. Such statements involve known / unknown risks, uncertainties and other factors and may cause and defer the actual results materially. Such factor
Slide 3: Contents
Contents Orchid Chemicals & Pharmaceuticals Ltd. Profile at a glance Multi-horizon business strategy and global strategic alliances Manufacturing Facilities APIs Dosage Forms Process Research, Pharma Research, NDDS and Biotechnology Capabilities overview Orchid Research Laboratories Ltd. Drug discov
Slide 4: Orchid Chemicals & Pharmaceuticals
Orchid Chemicals & Pharmaceuticals Vertically integrated global pharmaceutical company Established research, manufacturing and marketing capabilities Business Multi-therapeutic, multi-product global business Active Pharmaceutical Ingredients (API), finished dosage forms and drug discovery Fully inte
Slide 5: Orchid's Domain Leadership
Orchid’s Domain Leadership Leader in high technology life-saving antibiotics ; cephalosporins, penicillins / betalactams and carbapenems Presence Presence Complex non-penicillin, non-cephalosporin products Amongst Amongst the the Top-15 Top-15 Indian Indian pharma pharma companies, companies, aa sta
Slide 6: Orchid's Vision is to…
Orchid’s Vision is to… Become an Integrated Pharmaceutical Corporation of Global Scale and Standing, with a Comprehensive Coverage from Discovery to Delivery Key Differentiators State-of-the-art Global Stringent R&D and End-to-end alliances quality, Manufacturing connectivity and regulatory Faciliti
Slide 7: Orchid Group Corporate Structure
Orchid Group Corporate Structure Orchid Chemicals & Pharmaceuticals Ltd. Orchid Research Laboratories Ltd., Wholly owned subsidiary for drug discovery and Chennai development NCPC Orchid Pharmaceuticals 50:50 joint venture for manufacture of sterile Company Ltd. China cephalosporin APIs in China Who
Slide 8: API facilities (Alathur, Chennai)
API facilities (Alathur, Chennai) Largest cephalosporin API manufacturing GMP - Approved (WHO) complex US-FDA – Approved (Nov’02, Sep’03 & Dec’06) Approved by US FDA, UK MHRA and EDQM – Approved (Sep’03) other international regulatory agencies MHRA – Approved (Jan’06) Variety of non-sterile and ster
Slide 9: API facilities (Aurangabad)
API facilities (Aurangabad) Multi-site API complex with dedicated facilities for Sterile Carbapenem Facility Penicillins Sterile Carbapenems ISPE, INTERPHEX and Pharmaceutical Processing Non-penicillin, Non-cephalosporins (NPNC) Facility Awards 2009 Facilities designed for automated production Manuf
Slide 10: Highlights of Orchid's Generics Contracts – US, EU model
Highlights of Orchid’s Generics Contracts – US, EU model Orchid has long term partnerships with leading global generic players in US and Europe to distribute its products in the respective markets. Orchid licenses the generic products in return for development cum licensing fees received from the pa
Slide 11: API Process R&D - Capabilities
API Process R&D - Capabilities Core competence in complex chemistry and development of both sterile and non sterile products; antibiotics and non-antibiotics Greater yields and Optimized material costs Expertise in: efficiencies Oral & Sterile products Synthesis of mg Safe & economic Sterile Crystal
Slide 12: Formulations R&D – Capabilities
Formulations R&D – Capabilities Cephalosporins Carbapenems Product Groups Penicillins Other antibiotics Non-antibiotics, covering several therapies Immediate release Controlled release Tablets Matrix, Reservoir based Capsules Gastro-retentive Powder for oral suspension Tablets Mini tablets Capsules
Slide 13: Novel Drug Delivery Systems (NDDS)
Novel Drug Delivery Systems (NDDS) A new initiative to support product life cycle management of established drugs Undertakes development of new dosage forms and strengths to enhance the efficacy and safety of existing drugs Develops novel combinations of existing drugs for better compliance and / or
Slide 14: Biotechnology R&D – Capabilities
Biotechnology R&D – Capabilities Replace Replaceexisting existingchemical chemicalmethods methodsofofmanufacturing manufacturingvarious variousAPI API&&intermediates intermediateswith with fermentation fermentation and enzymatic based transformations to increase the efficiency and improvethe and enz
Slide 15: Orchid Research Laboratories Limited (ORLL)
Orchid Research Laboratories Limited (ORLL) A wholly owned subsidiary of Orchid Chemicals & Pharmaceuticals for undertaking drug discovery and development Business Business An integrated research company with end-to-end capabilities in drug discovery and development Among the top ranked pharmaceutic
Slide 16: ORLL's product and services strategy
ORLL’s product and services strategy Proprietary Drug Discovery Multiple TAs PCC in animals POC in humans Collaborative Drug Discovery Out-licensing MNC oriented Therapeutic area based Risk-reward shared models Project based services Pfizer Biovitrum Dermact etc. FTE or Fee for Service models www.or
Slide 17: IPM
IPM Draft, file and prosecute high quality patent applications Patent Applications Filed : Total - 644 14 28 Over 640 patent applications filed in various national 16 and international patent offices Includes 187 patent applications for NCEs, 28 for NDDS and 14 for biotech 399 187 Several patent and
Slide 18: Competencies in chemistry and related domains
Competencies in chemistry and related domains Molecular Modeling Structure based as well as ligand based modeling utilizing databases and software Prediction of activity of NCEs based on docking studies and pharmacophore / QSAR Prediction of ADME, toxicity for NCEs and impurities using databases and
Slide 19: Competencies in chemistry and related domains
Competencies in chemistry and related domains Analytical Chemistry Complete suite of sophisticated instrumentation including NMR, LCMS / MS, Headspace GC, HPLC, GCMS, Ion Chromatograph, XRD and Polarimeter Method development and validation, isolation and profiling of impurities, polymorph and metabo
Slide 20: Animal house facility
Animal house facility GLP Certified Facility 15000 sq.ft area Salient Salient features features CPCSEA approved Class 10000 area Governed by ethics committee 100% Power back up Double corridor rooms with 12-15 Fresh air changes per differential pressure to hour Design HEPA filters in all the rooms m
Slide 21: Competencies in biology and related domains
Competencies in biology and related domains Microbiology Facility In-vitro microbiology laboratory with contained work stations, equipped with BSC-A2 cabinets, spiral plater, QCount, Anoxomat etc. for multiple anti- infective studies Biosafety level 2 in-vivo facility with contained work stations fo
Slide 22: Competencies in biology and related domains
Competencies in biology and related domains Pre-form / formulation and DMPK Pre-clinical formulation by salt selection, micro-emulsion, complexation and co-solvent techniques Selection of vehicles for pharmocological studies, stability assessments, sample analysis and documentation Per oral, intrave
Slide 23: ORLL's multi-therapeutic, multi-lead discovery program
ORLL’s multi-therapeutic, multi-lead discovery program NCE Development Status Therapeutic Early Late Regulatory Phase 1 Phase II NCE Discovery Segment Pre-clinical Pre-Clinical Toxicology Clinical Clinical Diabetes 1 Tyrosine-TZD, Non-PPAR molecule 2 DPP IV Inhibitor 3 Novel Inflammation 1 Th1 / Th2
Slide 24: Business Transfer Agreement with Hospira
Business Business Transfer Transfer Agreement Agreement with with Hospira Hospira www.orchidpharma.com 24
Slide 25: Transaction Overview
Transaction Overview Orchid and Hospira have entered into a Business Transfer Agreement under aegis of which Orchid has transferred its generic injectable pharmaceuticals business to Hospira Total consideration of US$ 400 million in cash paid by Hospira to Orchid on Close of the Transaction Transact
Slide 26: Transaction Rationale for Orchid
Transaction Rationale for Orchid Strategic Rationale Underlines its ability to develop value-added, niche skill-sets in the global pharmaceuticals value chain, and monetize them Further fortifies its business model with long-term contractual API revenue streams; Enhances its financial flexibility to
Slide 27: Orchid's multi-horizon strategy would focus on a larger basket of oral products
Orchid’s multi-horizon strategy would focus on a larger basket of oral products and new value adding niche opportunities Horizon 3 – Innovation New Drug Discovery Novel Drug Delivery Horizon 2 - Formulations CRAMS Generics for regulated markets Branded for emerging markets Horizon 1 - API Branded fo
Slide 28: Orchid's Value Proposition
Orchid’s Value Proposition API Formulations Innovation GLOBAL DOMESTIC GLOBAL CRAMS NDDS NCEs APIs FORMULATIONS GENERICS (ORAL) State-of-the-art manufacturing infrastructure; two API sites, one oral generic formulations facility for advanced markets, two formulations facilities for certain emerging
Slide 29: Thank You
THANK YOU For any information or clarifications, please visit www.orchidpharma.com or call Ch Ram, Head – Communications & Investor Relations on +91 98400 11626 / [email protected] www.orchidpharma.com 29
Orchid Chemicals & Pharmaceuticals — Investor Presentation (April 2010) on 6ix